CEL-SCI'S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment
yahoo.com
news
2022-10-17 12:50:00

5 patients had no tumor left following a 3-week treatment of CEL-SCI's investigational drug Multikine

Images clearly show tumors in the patients' oral cavity prior to treatment with Multikine and the disappearance of these tumors before any subsequent standard-of-care treatment, confirmed at surgery

There were also partial responses of greater than 30% tumor burden reduction resulting from the Multikine treatment prior to subsequent standard of care treatment

VIENNA, Va., October 17, 2022--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced the availability to the public of an oral presentation delivered by Dr.
